Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 10 von 34

Details

Autor(en) / Beteiligte
Titel
One‐year persistence of neutralizing anti‐SARS‐CoV‐2 antibodies in dialysis patients recovered from COVID‐19
Ist Teil von
  • Hemodialysis international, 2021-10, Vol.25 (4), p.E53-E56
Ort / Verlag
Hoboken, USA: John Wiley & Sons, Inc
Erscheinungsjahr
2021
Quelle
Wiley Blackwell Single Titles
Beschreibungen/Notizen
  • The immunological mechanisms that modulate immune response to SARS‐CoV‐2 infection remain elusive. Little is known on the magnitude and the durability of antibody response against COVID‐19. There is consensus that patients with immune dysfunction, such as dialysis patients, may be unable to mount a robust and durable humoral immunity after infections. Recent studies showed that dialysis patients seroconverted after COVID‐19, but data on the durability of the immune response are missing. We reported the data of a durable anti‐spike protein seroconversion after natural SARS‐CoV‐2 infection in three patients on hemodialysis with a mean age of 67.2 ± 13.8 years. A mean antibody titer of 212.6 ± 174.9 UA/ml (Liaison®, DiaSorin) was found after one year (range, 366–374 days) from the diagnosis of COVID‐19. In conclusion, this case series provided evidence that patients receiving hemodialysis who recovered from severe COVID‐19 were able to mount a long‐lasting immune response against SARS‐CoV‐2. Although the protective capacity of this long‐term immunity remains to be determined, these patients did not report signs of reinfection after recovery from COVID‐19.
Sprache
Englisch
Identifikatoren
ISSN: 1492-7535
eISSN: 1542-4758
DOI: 10.1111/hdi.12963
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8597126

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX